This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Srinivasan, G. Articles by Dilsizian, V. Search for Related Content PubMed PubMed Citation Articles by Srinivasan, G. Articles by Dilsizian, V.

(Circulation. 1998;97:843-850.)
© 1998 American Heart Association, Inc.

Clinical Investigation and Reports

[¹⁸F]Fluorodeoxyglucose Single Photon Emission Computed Tomography

Can It Replace PET and Thallium SPECT for the Assessment of Myocardial Viability?

Gopal Srinivasan, MD; Anastasia N. Kitsiou, MD; Stephen L. Bacharach, PhD; Marissa L. Bartlett, PhD; Claiborne Miller-Davis, RN; ; Vasken Dilsizian, MD

From the Cardiology Branch, National Heart, Lung, and Blood Institute and the Department of Nuclear Medicine, National Institutes of Health, Bethesda, Md.

Correspondence to Gopal Srinivasan, MD, National Institutes of Health, 10 Center Dr, MSC 1650, Cardiology Branch, NHLBI, Building 10, Room 7B-15, Bethesda, MD 20892-1650.

Background—New high-energy collimators for single photon emission computed tomography (SPECT) cameras have made imaging of positron-emitting tracers, such as [¹⁸F]fluorodeoxyglucose (¹⁸FDG), possible. We examined differences between SPECT and PET technologies and between ¹⁸FDG and thallium tracers to determine whether ¹⁸FDG SPECT could be adopted for assessment of myocardial viability.

Methods and Results—Twenty-eight patients with chronic coronary artery disease (mean left ventricular ejection fraction [LVEF]=33±15% at rest) underwent ¹⁸FDG SPECT, ¹⁸FDG PET, and thallium SPECT studies. Receiver operating characteristic curves showed overall good concordance between SPECT and PET technologies and thallium and ¹⁸FDG tracers for assessing viability regardless of the level of ¹⁸FDG PET cutoff used (40% to 60%). However, in the subgroup of patients with LVEF25%, at 60% ¹⁸FDG PET threshold value, thallium tended to underestimate myocardial viability. In a subgroup of regions with severe asynergy, there were considerably more thallium/¹⁸FDG discordances in the inferior wall than elsewhere (73% versus 27%, P<.001), supporting attenuation of thallium as a potential explanation for the discordant observations. When uptake of ¹⁸FDG by SPECT and PET was compared in 137 segments exhibiting severely irreversible thallium defects (scarred by thallium), 59 (43%) were viable by ¹⁸FDG PET, of which 52 (88%) were also viable by ¹⁸FDG SPECT. However, of the 78 segments confirmed to be nonviable by ¹⁸FDG PET, 57 (73%) were nonviable by ¹⁸FDG SPECT (P<.001).

Conclusions—Although ¹⁸FDG SPECT significantly increases the sensitivity for detection of viable myocardium in tissue declared nonviable by thallium (to 88% of the sensitivity achievable by PET), it will occasionally (27% of the time) result in falsely identifying as viable tissue that has been identified as nonviable by both PET and thallium.

Key Words: myocardium • coronary disease • tomography • radioisotopes • nuclear medicine

This article has been cited by other articles:

				S. H. Rahimtoola, V. Dilsizian, C. M. Kramer, T. H. Marwick, and J.-L. J. Vanoverschelde Chronic ischemic left ventricular dysfunction from pathophysiology to imaging and its integration into clinical practice. J. Am. Coll. Cardiol. Img., July 1, 2008; 1(4): 536 - 555. [Abstract] [Full Text] [PDF]

				A. F.L. Schinkel, D. Poldermans, V. Rizzello, R. T. van Domburg, R. Valkema, A. Elhendy, E. Biagini, E. P. Krenning, M. L. Simoons, and J. J. Bax Impact of Diabetes Mellitus on Prediction of Clinical Outcome After Coronary Revascularization by 18F-FDG SPECT in Patients with Ischemic Left Ventricular Dysfunction J. Nucl. Med., January 1, 2006; 47(1): 68 - 73. [Abstract] [Full Text] [PDF]

				A. F L Schinkel, J. J Bax, and D. Poldermans Clinical assessment of myocardial hibernation Heart, January 1, 2005; 91(1): 111 - 117. [Full Text] [PDF]

				S. Graf, M. Gyongyosi, A. Khorsand, S. G. Nekolla, C. Pirich, K. Kletter, R. Dudczak, D. Glogar, G. Porenta, and H. Sochor Electromechanical Properties of Perfusion/Metabolism Mismatch: Comparison of Nonfluoroscopic Electroanatomic Mapping with 18F-FDG PET J. Nucl. Med., October 1, 2004; 45(10): 1611 - 1618. [Abstract] [Full Text] [PDF]

				A. F.L. Schinkel, J. J. Bax, R. Valkema, A. Elhendy, R. T. van Domburg, E. C. Vourvouri, M. A. Bountioukos, E. P. Krenning, J. R.T.C. Roelandt, and D. Poldermans Effect of Diabetes Mellitus on Myocardial 18F-FDG SPECT Using Acipimox for the Assessment of Myocardial Viability J. Nucl. Med., June 1, 2003; 44(6): 877 - 883. [Abstract] [Full Text] [PDF]

				A. Keck, K. Hertting, Y. Schwartz, R. Kitzing, M. Weber, B. Leisner, C. Franke, E. Bahlmann, C. Schneider, T. Twisselmann, et al. Electromechanical mapping for determination of myocardial contractility and viability: A comparison with echocardiography, myocardial single-photon emission computed tomography, and positron emission tomography J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1067 - 1074. [Abstract] [Full Text] [PDF]

				I. Matsunari, T. Yoneyama, S. Kanayama, M. Matsudaira, K. Nakajima, J. Taki, S. G. Nekolla, N. Tonami, and K. Hisada Phantom Studies for Estimation of Defect Size on Cardiac 18F SPECT and PET: Implications for Myocardial Viability Assessment J. Nucl. Med., October 1, 2001; 42(10): 1579 - 1585. [Abstract] [Full Text] [PDF]

				K.-C. Koch, J. vom Dahl, M. Wenderdel, B. Nowak, W. M. Schaefer, A. Sasse, C. Stellbrink, U. Buell, and P. Hanrath Myocardial viability assessment by endocardial electroanatomic mapping: comparison with metabolic imaging and functional recovery after coronary revascularization J. Am. Coll. Cardiol., July 1, 2001; 38(1): 91 - 98. [Abstract] [Full Text] [PDF]

				E. V.R. Di Bella, D. J. Kadrmas, and P. E. Christian Feasibility of Dual-Isotope Coincidence/Single-Photon Imaging of the Myocardium J. Nucl. Med., June 1, 2001; 42(6): 944 - 950. [Abstract] [Full Text] [PDF]

				J. E. Udelson Testing our tests: surrogate end points versus driving patient management and outcomes J. Am. Coll. Cardiol., January 1, 2001; 37(1): 89 - 92. [Full Text] [PDF]

				J. J. Bax, F. C. Visser, D. Poldermans, A. Elhendy, J. H. Cornel, E. Boersma, R. Valkema, A. van Lingen, P. M. Fioretti, and C. A. Visser Relationship Between Preoperative Viability and Postoperative Improvement in LVEF and Heart Failure Symptoms J. Nucl. Med., January 1, 2001; 42(1): 79 - 86. [Abstract] [Full Text] [PDF]

				A. Tawakol and H. Gewirtz Does CABG Improve Left Ventricular Ejection Fraction in Patients with Ischemic Cardiomyopathy, and Does It Matter? J. Nucl. Med., January 1, 2001; 42(1): 87 - 0. [Full Text] [PDF]

				G. A. Beller and B. L. Zaret Contributions of Nuclear Cardiology to Diagnosis and Prognosis of Patients With Coronary Artery Disease Circulation, March 28, 2000; 101(12): 1465 - 1478. [Full Text] [PDF]

				H. Sato, T. Iwasaki, T. Toyama, Y. Kaneko, T. Inoue, K. Endo, and R. Nagai Prediction of Functional Recovery After Revascularization in Coronary Artery Disease Using 18F-FDG and 123I-BMIPP SPECT* Chest, January 1, 2000; 117(1): 65 - 72. [Abstract] [Full Text] [PDF]

				K. Morimoto, H. Tomoda, M. Yoshitake, N. Aoki, S. Handa, and Y. Suzuki Prediction of Coronary Artery Lesions in Unstable Angina by Iodine 123 Beta-Methyl Iodophenyl Pentadecanoic Acid (BMIPP), a Fatty Acid Analogue, Single Photon Emission Computed Tomography at Rest Angiology, August 1, 1999; 50(8): 639 - 648. [Abstract] [PDF]

				H. Jadvar, H. W. Strauss, and G. M. Segall SPECT and PET in the Evaluation of Coronary Artery Disease RadioGraphics, July 1, 1999; 19(4): 915 - 926. [Abstract] [Full Text] [PDF]

				J. E. Udelson Steps Forward in the Assessment of Myocardial Viability in Left Ventricular Dysfunction Circulation, March 10, 1998; 97(9): 833 - 838. [Full Text] [PDF]